Evidence map›Paper›PMID 23145905›Full record

ReviewInternational wound journal2012

Extending the TIME concept: what have we learned in the past 10 years?(*).

David J Leaper, Gregory Schultz, Keryln Carville, Jacqueline Fletcher, Theresa Swanson, Rebecca Drake

2 registry-linked trialsAbstract readReview
In one paragraph

Review in International wound journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 110 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03369756 naterminatednot on this mapstarted 2018, after this paper: background citation

A Prospective Study of Quality of Life in Patients With Chronic Leg Wound(s) Treated With Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel

TypeinterventionalSponsorB. Braun Medical Inc.Ran2018 to 2019Enrolled43ConditionsWound of Lower Leg (Physical Finding)ArmsProntosan Wound Irrigation Solution and Prontosan Wound Gel
NCT07316192 narecruitingnot on this mapstarted 2025, after this paper: background citation

Outcomes With Pelashield™ PainGuard™ Compared to Restrata® in Standard Two-Stage Excision and Closure for Hidradenitis Suppurativa: A Prospective Cohort With Retrospective Comparator

TypeinterventionalSponsorRutgers, The State University of New JerseyRan2025 to 2026Enrolled10ConditionsHidradenitis Suppurativa (HS)ArmsPelashield Painguard
3 · Its place in the literature

Who cites it

110 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. M.O.I.S.T. Concept for the Local Therapy of Chronic Wounds: An International Update.The international journal of lower extremity wounds · 2026
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Clinical Evaluation of AMNIODERM+Biotech (Basel (Switzerland)) · 2024
    Article
  20. Review

50 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

David J LeaperSection of Wound Healing, Institute for Translation, Innovation, Methodology and Engagement, Cardiff University, Cardiff, UK. profdavidleaper@doctors.co.uk
Gregory Schultz
Keryln Carville
Jacqueline Fletcher
Theresa Swanson
Rebecca Drake

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The TIME acronym (tissue, infection/inflammation, moisture balance and edge of wound) was first developed more than 10 years ago, by an international group of wound healing experts, to provide a framework for a structured approach to wound bed preparation; a basis for optimising the management of open chronic wounds healing by secondary intention. However, it should be recognised that the TIME principles are only a part of the systematic and holistic evaluation of each patient at every wound assessment. This review, prepared by the International Wound Infection Institute, examines how new data and evidence generated in the intervening decade affects the original concepts of TIME, and how it is translated into current best practice. Four developments stand out: recognition of the importance of biofilms (and the need for a simple diagnostic), use of negative pressure wound therapy (NPWT), evolution of topical antiseptic therapy as dressings and for wound lavage (notably, silver and polyhexamethylene biguanide) and expanded insight of the role of molecular biological processes in chronic wounds (with emerging diagnostics and theranostics). Tissue: a major advance has been the recognition of the value of repetitive and maintenance debridement and wound cleansing, both in time-honoured and novel methods (notably using NPWT and hydrosurgery). Infection/inflammation: clinical recognition of infection (and non infective causes of persisting inflammation) is critical. The concept of a bacterial continuum through contamination, colonisation and infection is now widely accepted, together with the understanding of biofilm presence. There has been a return to topical antiseptics to control bioburden in wounds, emphasised by the awareness of increasing antibiotic resistance. Moisture: the relevance of excessive or insufficient wound exudate and its molecular components has led to the development and use of a wide range of dressings to regulate moisture balance, and to protect peri-wound skin, and optimise healing. Edge of wound: several treatment modalities are being investigated and introduced to improve epithelial advancement, which can be regarded as the clearest sign of wound healing. The TIME principle remains relevant 10 years on, with continuing important developments that incorporate new evidence for wound care.

Indexed as

Wound HealingAbbreviations as TopicAnti-Bacterial AgentsAnti-Infective Agents, LocalAnxietyBandagesBiguanidesBiofilmsDebridementDisinfectantsDisinfectionDrug Resistance, BacterialElectromagnetic FieldsExudates and TransudatesHoneyHumansAnti-Bacterial AgentsAnti-Infective Agents, LocalBiguanidescadexomer iodineDisinfectantsIodophorspolihexanideSilver CompoundsSilver Sulfadiazine

Identifiers

PMID23145905
PMCPMC7950760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.